Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Pregnancy and Childbirth
Published in: BMC Pregnancy and Childbirth 1/2018

Open Access 01-12-2018 | Debate

Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?

Authors: Alastair Macfarlane, Trisha Greenhalgh

Published in: BMC Pregnancy and Childbirth | Issue 1/2018

Login to get access

Abstract

Background

Despite significant teratogenic risks, sodium valproate is still widely prescribed in many countries to women of childbearing age, as a mood stabiliser in bipolar disorder and also in epilepsy. The UK has recently banned valproate use in women who are not in a pregnancy prevention programme. Whilst this ruling reflects prevailing clinical practice, it also highlights an ongoing debate about when (if ever) a woman who is or could become pregnant should be allowed to choose to take valproate.

Main body

We review the benefits and harms of drugs available for bipolar disorder and epilepsy in women of childbearing age, with a particular focus on teratogenic risk. We speculate on hypothetical rare situations in which potential benefits of valproate may outweigh potential harms in such women. We also review the literature on shared decision-making – on which there is now a NICE guideline and numerous evidence-based decision tools. Drawing on previous work by experts in shared decision-making, we offer a list of ‘frequently asked questions’ and a matrix of options to support conversations with women about continuing or discontinuing the drug in (or in anticipation of) pregnancy. We also consider whether shared decision-making is an appropriate paradigm when considering whether to continue a teratogenic drug.

Conclusion

We conclude that because valproate in pregnancy remains the subject of such debate, there is scope for further research – not only into the relative efficacy and safety of alternatives to it – but also into the dynamics of communication and shared decision-making in this situation.
Literature
1.
Vargesson N. Thalidomide-induced limb defects: resolving a 50-year-old puzzle. Bioessays. 2009;31(12):1327–36.PubMedCrossRef
2.
Casassus B: France bans sodium valproate use in case of pregnancy. Lancet 2017, 390(10091):217–217.
3.
Epilepsy in Pregnancy. Green Top Guidelines. Royal College of Obstetricians and Gynaecologists. 2016:68.
4.
National Institute of Health and Clinical Excellence: Bipolar disorder: Assessment and management. In., vol. Clinical guideline CG185; 2014.
5.
6.
Iacobucci G. MHRA bans valproate prescribing for women not in pregnancy prevention programme. BMJ. 2018:361, 1823.
7.
Nevitt SJ, Sudell M, Weston J, Smith CT, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;6:237.
8.
Moller HJ, Nasrallah HA. Treatment of bipolar disorder. J Clin Psychiatry. 2003;64:9–17.PubMed
9.
Molgaard-Nielsen D, Hviid A. Newer generation antiepileptic drugs and the risk of major birth defects. JAMA-J Am Med Assoc. 2011;305(19):1996–2002.CrossRef
10.
Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ-British Medical Journal. 2014;348:18.CrossRef
11.
Atturu H, Odelola A. Valproate prescribing in women of childbearing age: an audit of clinical practice. Advances in Psychiatry. 2015;2015:1–6.CrossRef
12.
Murphy S, Bennett K, Doherty CP. Prescribing trends for sodium valproate in Ireland. Seizure. 2016;36:44–8.PubMedCrossRef
13.
Kaplan YC, Abdelkader N. Valproate prescribing trends for non-epilepsy indications in women of reproductive age warrants effective measures and increased surveillance. Seizure. 2016;40:13–4.PubMedCrossRef
14.
15.
Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, et al. Cross-national epidemiology of major depression and bipolar disorder. Jama-Journal of the American Medical Association. 1996;276(4):293–9.CrossRef
16.
Pompili M, Gonda X, Serafini G, Innamorati M, Sher L, Amore M, Rihmer Z, Girardi P. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord. 2013;15(5):457–90.PubMedCrossRef
17.
Hunt GE, Malhi GS, Cleary M, Lai HMX, Sitharthan T. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: systematic review and meta-analysis. J Affect Disord. 2016;206:331–49.PubMedCrossRef
18.
Di Florio A, Craddock N, van den Bree M. Alcohol misuse in bipolar disorder: a systematic review and meta-analysis of comorbidity rates. Eur Psychiat. 2014;29(3):117–24.CrossRef
19.
Amerio A, Odone A, Liapis CC, Ghaemi SN. Diagnostic validity of comorbid bipolar disorder and obsessive compulsive disorder: a systematic review. Acta Psychiatr Scand. 2014;129(5):343–58.PubMedCrossRef
20.
Wingo AP, Ghaemi SN. A systematic review of rates and diagnostic validity of comorbid adult attention deficit hyperactivity disorder and bipolar disorder. J Clin Psychiatry. 2007;68(11):1776–84.PubMedCrossRef
21.
Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, Sachs GS, Nierenberg AA, Thase ME, Pollack MH, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiat. 2004;161(12):2222–9.PubMedCrossRef
22.
Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry. 2002;63(2):120–5.PubMedCrossRef
23.
Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatr. 2002;47(5):426–36.CrossRef
24.
Fisher RS, Boas WV, Blume W, Elger C, Genton P, Lee P, Engel J. Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470–2.PubMedCrossRef
25.
26.
Zupanc ML. Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy. Neurology. 2006;66(6):S37–45.PubMedCrossRef
27.
Tomson T. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology. 2006;66(3):354–60.CrossRef
28.
Petersen I, Collings SL, McCrea RL, Nazareth I, Osborn DP, Cowen PJ, Sammon CJ. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clin Epidemiol. 2017;9:95–103.PubMedPubMedCentralCrossRef
29.
Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry. 2002;63(2):146–51.PubMedCrossRef
30.
Taylor D, Paton C, Kapur S: Maudsley prescribing guidelines, Tenth Edition; 2009.CrossRef
31.
Nasrallah HA, Ketter TA, Kalali AH. Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. J Affect Disord. 2006;95(1–3):69–78.PubMedCrossRef
32.
Pope HG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania: a placebo controlled study. Arch Gen Psychiatry. 1991;48(1):62–8.PubMedCrossRef
33.
Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, Salanti G, Motomura K, Shimano-Katsuki S, Leucht S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351–9.PubMedCrossRef
34.
Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol. 2012;22(5):339–46.PubMedCrossRef
35.
Boden R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. Br Med J. 2012;345:10.CrossRef
36.
37.
Trinka E. Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients? Acta Neurol Scand. 2012;126:10–8.CrossRef
38.
Pagano HP, Zapata LB, Berry-Bibee EN, Nanda K, Curtis KM. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception. 2016;94(6):641–9.PubMedCrossRef
39.
Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB, Antiepileptic Drug Pregnancy R. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology. 2005;64(6):961–5.PubMedCrossRef
40.
Thisted E, Ebbesen F. Malformations, withdrawal manifestations and hypoglycaemia after exposure to valproate in utero. Arch Dis Child. 1993;69(3):288–91.PubMedPubMedCentralCrossRef
41.
Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol. 2009;28(1):1–10.PubMedCrossRef
42.
Semmler A, Frisch C, Bleul C, Smith D, Bigler L, Prost JC, Blom H, Linnebank M. Intrauterine valproate exposure is associated with alterations in hippocampal cell numbers and folate metabolism in a rat model of valproate teratogenicity. Seizure. 2017;46:7–12.PubMedCrossRef
43.
Roullet FI, Lai JKY, Foster JA. In utero exposure to valproic acid and autism: a current review of clinical and animal studies. Neurotoxicol Teratol. 2013;36:47–56.PubMedCrossRef
44.
Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, Garica-Finana M, Kneen R, Lucas SB, Shallcross R, Baker GA, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013;84(6):637–43.PubMedPubMedCentralCrossRef
45.
Arkilo D, Vaou EO. Antiepileptic drug use during pregnancy: sodium valproate is associated with lower offspring IQ. Evidence-based nursing. 2015;18(4):109.PubMedCrossRef
46.
Schneider T, Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology. 2005;30(1):80–9.PubMedCrossRef
47.
Ranger P, Ellenbroek BA. Perinatal influences of valproate on brain and behaviour: an animal model for autism. Curr Top Behav Neurosci. 2016;29:363–86.PubMedCrossRef
48.
Williams G, King J, Cunningham M, Stephan M, Kerr B, Hersh JH. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol. 2001;43(3):202–6.PubMedCrossRef
49.
Beezhold JN, Fagard D, Harabajiu C: Valproate used during pregnancy: what should be done? Eur Psychiat 2017, 41:S419-S419.
50.
Briggs G, Freeman R. Drugs in pregnancy and lactation, 11th edition: Wolters: Kluwer; 2017.
51.
Ingram JL, Peckham SM, Tisdale B, Rodier PM. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol. 2000;22(3):319–24.PubMedCrossRef
52.
Yang EJ, Ahn S, Lee K, Mahmood U, Kim HS. Early behavioral abnormalities and perinatal alterations of PTEN/AKT pathway in valproic acid autism model mice. PLoS One. 2016;11(4):17.
53.
Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, den Berg LTW d J-v. Workin EAS: Valproic acid monotherapy in pregnancy and major congenital malformations Acid Monotherapy in Pregnancy and Major Congenital Malformations. N Engl J Med. 2010;362(23):2185–93.PubMedCrossRef
54.
Alsdorf R, Wyszynski DF. Teratogenicity of sodium valproate. Expert Opin Drug Saf. 2005;4(2):345–53.PubMedCrossRef
55.
Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Cook M, Lander C, Eadie MJ. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci. 2004;11(8):854–8.PubMedCrossRef
56.
Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs. 2008;22(4):325–34.PubMedCrossRef
57.
Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, Zurick A, Cohen LS. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiat. 2007;164(12):1817–24.PubMedCrossRef
58.
Stewart DE. Prophylactic lithium in postpartum affective psychosis. J Nerv Ment Dis. 1988;176(8):485–9.PubMedCrossRef
59.
Stewart DE, Klompenhouwer JL, Kendell RE, Vanhulst AM. Prophylactic lithium in puerperal psychosis: the experience of 3 centres. Br J Psychiatry. 1991;158:393–7.PubMedCrossRef
60.
Austin MPV. Puerperal affective psychosis: is there a case for lithium prophylaxis? Br J Psychiatry. 1992;161:692–4.PubMedCrossRef
61.
Howland RH. Potential adverse effects of discontinuing psychotopic drugs part 1: adrenergic cholergic and histamine drugs. J Psychosoc Nurs Ment Health Serv. 2010;48(6):11–4.CrossRef
62.
Sharma P, Kongasseri S, Praharaj SK. Outcome of mood stabiliser discontinuation in bipolar disorder after 5 years of euthymia. J Clin Psychopharmacol. 2014;34(4):504–7.PubMedCrossRef
63.
Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2013;10:76.
64.
Koksal A, Dirican AC, Altunkaynak Y, Yildirim EA. First manic episode due to discontinuation of valproic acid in a patient with epilepsy. J Neuropsychiatr Clin Neurosci. 2014;26(2):E60–1.CrossRef
65.
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F, Grp ES. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: observations from EURAP. Epilepsia. 2016;57(8):E173–7.PubMedCrossRef
66.
Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987;150:662–73.PubMedCrossRef
67.
Harlow BL, Vitonis AF, Sparen P, Cnattingius S, Joffe H, Hultman CM. Incidence of hospitalization for postpartum psychotic and bipolar episodes in women with and without prior prepregnancy or prenatal psychiatric hospitalizations. Arch Gen Psychiatry. 2007;64(1):42–8.PubMedCrossRef
68.
69.
Friedman SH, Sorrentino R. Postpartum psychosis, infanticide, and insanity: implication for forensic psychiatry. J Am Acad Psychiatry Law. 2012;40(3):326–32.
70.
Kapfhammer H-P, Lange P. Suicidal and infanticidal risks in puerperal psychosis of an early onset. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater. 2012;26(3):129–38.
71.
Hollins K. Consequences of antenatal mental health problems for child health and development. Curr Opin Obstet Gynecol. 2007;19(6):568–72.PubMedCrossRef
72.
Garcia-Portilla MP, Bobes J. Preventive recommendations on the use of valproic acid in pregnant or gestational women to be very present. Rev Psiquiatr Salud Ment. 2017;10(3):129–33.PubMedCrossRef
73.
Kmietowicz Z. Women are unaware of pregnancy risks linked with sodium valproate. BMJ. 2016;355:2.
74.
Black KI, Day CA. Improving access to long acting contraceptive methods and reducing unplanned pregnancy among women with substance use disorders. Substance Abuse Research and Treatment. 2016;10:27–33.PubMedPubMedCentral
75.
Johnson BR, Ndhlovu S, Farr SL, Chipato T. Reducing unplanned pregnancy and abortion in Zimbabwe through postabortion contraception. Stud Fam Plan. 2002;33(2):195–202.CrossRef
76.
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F, Grp ES. Dose dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology. 2015;85(10):866–72.PubMedCrossRef
77.
McGirr A, Vohringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry. 2016;3(12):1138–46.PubMedCrossRef
78.
Huybrechts KF, Hernandez-Diaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, Cohen JM, Panchaud A, Cohen L, Bateman BT. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938–46.PubMedPubMedCentralCrossRef
79.
Kaplan Y. Lamotrigine for epilepsy may not increase risk of birth defects, study shows. BMJ. 2016;353
80.
Larsen ER, Saric K. Pregnancy and bipolar disorder: the risk of recurrence when discontinuing treatment with mood stabilisers: a systematic review. Acta neuropsychiatrica. 2016:1–8.
81.
Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations: have newer agents altered clinical outcomes? Epilepsy Res. 2012;98(2–3):194–8.PubMedCrossRef
82.
Legare F, Thompson-Leduc P. Twelve myths about shared decision making. Patient Educ Couns. 2014;96(3):281–6.PubMedCrossRef
83.
Herxheimer A. Communicating with patients about harms and risks. PLoS Med. 2005;2(2):91–2.CrossRef
84.
Pickrell WO, Elwyn G, Smith PEM. Shared decision making in epilepsy management. Epilepsy Behav. 2015;47:78–82.PubMedCrossRef
85.
Joosten EAG, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CPF, de Jong CAJ. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom. 2008;77(4):219–26.PubMedCrossRef
86.
Austin CA, Mohottige D, Sudore RL, Smith AK, Hanson LC. Tools to promote shared decision making in serious illness: a systematic review. JAMA Intern Med. 2015;175(7):1213–21.PubMedPubMedCentralCrossRef
87.
Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, Cording E, Tomson D, Dodd C, Rollnick S, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–7.PubMedPubMedCentralCrossRef
88.
Downing C, Biers J, Larson C, Kimball A, Wright H, Ishii T, Gilliam D, Johnson T. Genetic and maternal effects on valproic acid teratogenesis in C57BL/6J and DBA/2J mice. Toxicol Sci. 2010;116(2):632–9.PubMedPubMedCentralCrossRef
89.
Ogawa T, Kuwagata M, Hori Y, Shioda S. Valproate-induced developmental neurotoxicity is affected by maternal conditions including shipping stress and environmental change during early pregnancy. Toxicol Lett. 2007;174(1–3):18–24.PubMedCrossRef
90.
91.
Lenox RH, Hahn CG. Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry. 2000;61:5–15.PubMed
92.
Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol. 1999;58(1):31–59.PubMedCrossRef
93.
Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int. 2000;37(2–3):103–10.PubMedCrossRef
94.
Xie XM, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology. 1998;38(3):119–30.PubMedCrossRef
95.
Ambrosio AF, Soares-da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002;27(1–2):121–30.PubMedCrossRef
96.
Post RM, Rubinow DR, Uhde TW. Biochemical mechanisms of action of carbamazepine in affective illness and epilepsy. Psychopharmacol Bull. 1984;20(3):585–9.PubMed
97.
Hertel P, Lindblom N, Nomikos GG, Svensson TH. Modulation of central serotonergic neurotransmission by risperidone: underlying mechanism s and significance of action. Prog Neuro-Psychopharmacol Biol Psychiatry. 1998;22(5):815–34.CrossRef
98.
Di Martino A, Zuddas A. Long-term risperidone treatment in pervasive developmental disorders: efficacy, safety, and putative mechanism of action. Consensus in Child Neurology. 2003:82–7.
99.
Li XM, Juorio AV, Chlan-Founey J, Shrikhande S, Bennett VL, Keegan DL. A new mechanism for the actions of olanzapine. Can J Psychiat-Rev Can Psychiat. 1999;44(6):605–6.
100.
Goldstein JM: Mechanism of action of quetiapine: a modulator of dopamine at the D2 receptor. Schizophr Res 2003, 60(1):311–311.
101.
Patorno E, Huybrechts KF, Bateman BT, Cohen JM, Desai RJ, Mogun H, Cohen LS, Hernandez-Diaz S. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017;376(23):2245–54.PubMedPubMedCentralCrossRef
102.
Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996;37:S34–44.PubMedCrossRef
103.
Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol. 2002;16(1):9–17.PubMedCrossRef
104.
de Haan GJ, Edelbroek P, Segers J, Engelsman M, Lindhout D, Devile-Notschaele M, Augustijn P. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology. 2004;63(3):571–3.PubMedCrossRef
105.
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F, Grp ES. Dose dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17.PubMedCrossRef
106.
Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, Liggan B, Irwin B, Delanty N, Hunt SJ, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland epilepsy and pregnancy registers. J Neurol Neurosurg Psychiatry. 2014;85(9):1029–34.PubMedCrossRef
Metadata
Title
Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?
Authors
Alastair Macfarlane
Trisha Greenhalgh
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Pregnancy and Childbirth / Issue 1/2018
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-018-1842-x

Other articles of this Issue 1/2018

BMC Pregnancy and Childbirth 1/2018 Go to the issue

Study protocol

A longitudinal, multi-centre, superiority, randomized controlled trial of internet-based cognitive behavioural therapy (iCBT) versus treatment-as-usual (TAU) for negative experiences and posttraumatic stress following childbirth: the JUNO study protocol

Research article

Dietary practices and associated factors during pregnancy in northwestern Ethiopia

Research article

Determinants of infant mortality for children of women prisoners: a longitudinal linked data study

Research article

Sociocultural determinants of nomadic women’s utilization of assisted childbirth in Gossi, Mali: a qualitative study

Research article

Not now but later – a qualitative study of non-exercising pregnant women’s views and experiences of exercise

Research article

Survival of low birthweight neonates in Uganda: analysis of progress between 1995 and 2011